News | October 20, 2022
Lupin to acquire two inhalation brands from Sunovion for US$75 million
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US
Sildenafil for Oral Suspension (RLD Revatio) had estimated annual sales of US $64 million in the US
Though lungs do not have the celebrity status as the heart, they are one of the most important and delicate organs of the human body
The companies will leverage their respective proprietary technology platforms
RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
Diclofenac Sodium Topical Solution USP, 2% w/w (RLD Pennsaid) had estimated annual sales of US $484 million in the US
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Olympus Corp was the market leader for endoscopy devices, accounting for around 23% of the global market in 2021.
The reliability of their products, evidenced by their inclusion in the WHO emergency use list, has further improved with the addition of Takara Bio's enzymes.
Subscribe To Our Newsletter & Stay Updated
